<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Progressive supranuclear palsy (PSP): Management and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Progressive supranuclear palsy (PSP): Management and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Progressive supranuclear palsy (PSP): Management and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stewart A Factor, DO
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christine Doss Esper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4229704462">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Progressive supranuclear palsy (PSP) is an atypical parkinsonian disorder characterized by vertical supranuclear gaze palsy and postural instability with unexplained falls. This topic will review the management and prognosis of PSP. Other aspects of PSP are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">
          "Multiple system atrophy: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         Other neurodegenerative parkinsonian syndromes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14135.html" rel="external">
          "Corticobasal degeneration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">
          "Multiple system atrophy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2796785422">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no treatments that alter the natural history of disease in PSP and no drugs that provide significant symptomatic benefits as seen with levodopa in Parkinson disease. However, several nonpharmacologic and pharmacologic supportive measures are available for the treatment of PSP.
        </p>
        <p class="headingAnchor" id="H1901630588">
         <span class="h2">
          Multidisciplinary interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         A multidisciplinary approach is essential, involving health care professionals from neurology, physical therapy, occupational therapy, speech pathology, nutrition, neuropsychology, psychiatry, social work, and palliative care [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietitians as well as speech and language therapists can help to manage dysphagia and dysarthria. Specific modalities for dysarthria include facial exercises, Lee Silverman Voice Treatment [
         <a href="#rid2">
          2,3
         </a>
         ], written communication, and a talking keyboard. Some experts advise routine swallowing evaluations (eg, every six months) to assess the risk for dysphagia and aspiration, which are major causes of mortality in patients with PSP [
         <a href="#rid1">
          1
         </a>
         ]. Treatments for dysphagia include head posturing, dietary changes, and percutaneous gastrostomy tube placement in more advanced cases. However, a gastrostomy tube does not diminish the risk of aspiration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early occupational therapy is essential in promoting longer independence in performing activities of daily living. Mirror-prism lenses can allow patients with severe limitation of extraocular movements to read and feed themselves [
         <a href="#rid4">
          4
         </a>
         ]. Eyelid crutches, alone or in combination with botulinum toxin therapy, may be useful for eyelid opening apraxia and blepharospasm, which can be severe enough to render a patient with PSP functionally blind [
         <a href="#rid5">
          5
         </a>
         ]. Decreased blink rate can be effectively treated with
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         , in addition to dark glasses to reduce photophobia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical therapy and aerobic exercise may provide symptomatic treatment for postural instability and falls, such as gait and balance training. Although supporting evidence for physical therapy and exercise is robust in patients with Parkinson disease, direct evidence in patients with PSP is more limited [
         <a href="#rid6">
          6-8
         </a>
         ]. An uncontrolled pilot study in 20 patients with PSP showed promising results from a customized exercise program including resistance training, balance training, and walking exercises, with measurable improvement in both the pull test and the Berg Balance Scale [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4899.html" rel="external">
          "Nonpharmacologic management of Parkinson disease", section on 'Exercise and physical therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Walking aides, such as weighted walkers and low-heel nonstick shoes, are recommended [
         <a href="#rid9">
          9,10
         </a>
         ]. The combination of frontal lobe disturbance and postural instability poses significant challenges in patients with PSP and contributes to even higher risks of falling. Fear of falls also correlates with increased anxiety and depression [
         <a href="#rid11">
          11
         </a>
         ]. Freezing of gait can be improved by the use of walkers with lasers, visual cues, rhythmic cues, and arc turns.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Palliative care needs may be present from the time of diagnosis. Advance care planning should be addressed as soon as possible [
         <a href="#rid12">
          12
         </a>
         ], ideally while the patients retain decision-making capacity, to express their wishes on the goals of care, future treatments such as artificial feeding, intensive care unit interventions, resuscitation status, the place of care, the place of death (eg, home, hospice, or hospital), making a will, and funeral plans. Palliative care in patients with parkinsonian disorders is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/97581.html" rel="external">
          "Palliative approach to Parkinson disease and parkinsonian disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1590659788">
         <span class="h2">
          Support groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         Caregivers experience significant burdens over the course of the disease [
         <a href="#rid13">
          13
         </a>
         ]. Expert nursing support and lay associations are invaluable for providing helpful information to families and caregivers. Local, regional, and national associations can play an integral role to benefit the lives of patients, families, and caregivers. These groups include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.psp.org%2F&amp;token=%2FydOckGcXt0QpwouWndQAWiYDKz%2Brb%2FJouzpq%2FwmJec%3D&amp;TOPIC_ID=113998" target="_blank">
          CurePSP
         </a>
         – North America
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pspassociation.org.uk%2F&amp;token=%2FydOckGcXt0QpwouWndQAfsKMRi9cWMFFqXOo0TQ9gFShhEsb8HXneV4LTvS88BS&amp;TOPIC_ID=113998" target="_blank">
          The PSP Association
         </a>
         – United Kingdom
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H119726134">
         <span class="h2">
          Pharmacologic treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurotransmitter replacement strategies have
         <strong>
          not
         </strong>
         had a major therapeutic impact in PSP.
        </p>
        <p>
         The main role of levodopa in patients with suspected PSP is diagnostic; a poor or unsustained response to levodopa therapy is generally observed in patients with PSP and can help to distinguish PSP from idiopathic Parkinson disease. (See
         <a class="medical medical_review" href="/z/d/html/14136.html" rel="external">
          "Progressive supranuclear palsy (PSP): Clinical features and diagnosis", section on 'Supportive features'
         </a>
         .)
        </p>
        <p>
         However, levodopa therapy may provide some degree of transient benefit, as suggested by several small retrospective reports. One study found that 4 of 12 patients with postmortem-confirmed PSP showed a "modest improvement" while receiving levodopa with a peripheral decarboxylase inhibitor [
         <a href="#rid14">
          14
         </a>
         ]. The improvement was not sustained and resulted in adverse effects in more than half of the patients. In a later report of 15 cases of autopsy-confirmed PSP, 9 showed some benefit to levodopa used in combination with other drugs, and 5 had some improvement on levodopa alone [
         <a href="#rid15">
          15
         </a>
         ]. However, the benefit was generally minimal and was observed only in the early stages of the disease.
        </p>
        <p>
         Therefore, a trial of levodopa is suggested for symptomatic treatment of patients with PSP who have disabling or troublesome parkinsonism to determine responsiveness. Although regimens vary, many experts suggest treating with levodopa 1000 to 1200 mg per day (up to 300 mg per dose) if tolerated for at least one month [
         <a href="#rid1">
          1
         </a>
         ]. The variant PSP with predominant parkinsonism (PSP-P) is often initially responsive, whereas the classic PSP with Richardson syndrome (PSP-RS) is generally not responsive to levodopa. Rare patients who respond to levodopa but do not tolerate higher oral doses may derive benefit from continuous intestinal gel delivery [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4897.html" rel="external">
          "Device-assisted and lesioning procedures for Parkinson disease", section on 'Continuous levodopa-carbidopa intestinal gel infusion'
         </a>
         .)
        </p>
        <p>
         A common side effect of levodopa in patients with PSP is visual hallucinations, although there have also been reports of dyskinesia [
         <a href="#rid14">
          14,17
         </a>
         ], oromandibular dystonia [
         <a href="#rid18">
          18
         </a>
         ], and apraxia of eyelid opening [
         <a href="#rid19">
          19
         </a>
         ]. Speech dysfunction potentially related to dystonia in a patient taking levodopa should be considered a possible side effect of the drug; a cautious trial of lowering the dose or discontinuing the drug may improve the speech difficulties.
        </p>
        <p>
         There are only limited data for a variety of other drugs that have been used for symptomatic treatment of PSP [
         <a href="#rid1">
          1,12,20
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Botulinum toxin injections can effectively treat various forms of focal dystonia and drooling.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          Amantadine
         </a>
         can provide a transient therapeutic benefit for gait, including freezing, and dysphagia in a minority of cases and can also help drooling and dyskinesia [
         <a href="#rid1">
          1,21-23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          Zolpidem
         </a>
         administration was associated with improved motor function in 2 of 10 patients compared with placebo or levodopa [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          Amitriptyline
         </a>
         has been assessed in a few patients with variable results for improvement of motor function [
         <a href="#rid23">
          23,25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cholinesterase inhibitors have been used to treat rare types of dementia but there are inadequate data to determine if they have any benefit in PSP [
         <a href="#rid27">
          27
         </a>
         ]. The results of one small trial suggested that
         <a class="drug drug_general" data-topicid="9383" href="/z/d/drug information/9383.html" rel="external">
          donepezil
         </a>
         may worsen motor function [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1150028781">
         <span class="h2">
          Other interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electroconvulsive therapy, while helpful in some patients with idiopathic Parkinson disease, has been used in a small number of patients with PSP with mixed results [
         <a href="#rid29">
          29,30
         </a>
         ]. Early anecdotal reports suggested negative results in patients with PSP who had neurosurgical treatments including pallidotomy and subthalamic or pallidal deep brain stimulation (DBS) [
         <a href="#rid31">
          31,32
         </a>
         ]. In a case report, DBS of the pedunculopontine nucleus was associated with modest benefit in a patient with PSP-P [
         <a href="#rid33">
          33
         </a>
         ]. However, there was no benefit of DBS in a subsequent trial of eight patients with PSP-RS who received unilateral pedunculopontine nucleus DBS and were randomly assigned to blinded evaluation in both the off-stimulation and on-stimulation states at 6 and 12 months [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         There has been interest in spinal cord stimulation (SCS) for gait disorders in Parkinson disease and related disorders. One small study examined this treatment modality in three patients with PSP-RS [
         <a href="#rid35">
          35
         </a>
         ]. Improvements in freezing-of-gait frequency, turning duration, step length, and stride velocity were observed, and ambulatory gait parameters improved by approximately 30 percent. Further studies are needed to confirm these findings [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H825632993">
         <span class="h2">
          Investigational therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Research into potential disease-modifying therapies for PSP has focused on agents with tau-active properties [
         <a href="#rid37">
          37,38
         </a>
         ]. One approach involves agents such as tideglusib, which inhibits a key enzyme (glycogen synthase kinase 3 beta) that plays a role in the hyperphosphorylation of tau [
         <a href="#rid39">
          39
         </a>
         ]. Another approach involves the neuroprotective agent davunetide, which is thought to maintain microtubule function, reduce tau phosphorylation, and inhibit apoptosis [
         <a href="#rid40">
          40
         </a>
         ]. Unfortunately, randomized placebo-controlled trials of tideglusib [
         <a href="#rid41">
          41
         </a>
         ] or davunetide [
         <a href="#rid42">
          42
         </a>
         ] for patients with PSP found no benefit.
        </p>
        <p>
         Treatments targeting tau aggregation, tau phosphorylation, and microtubule stabilization are also under investigation in PSP [
         <a href="#rid43">
          43
         </a>
         ]. The anti-tau monoclonal antibody tilavonemab (ABBV-8E12), which targets extracellular tau fragments, was safe and well tolerated in a multicenter trial of 378 patients but did not alter disease course compared with placebo and was terminated when prespecified futility criteria were met [
         <a href="#rid44">
          44
         </a>
         ]. A similar fate was found with BIIB092, which did not show efficacy on the primary endpoint (change in PSP-RS at one year) or secondary endpoints in a phase II randomized controlled trial [
         <a href="#rid45">
          45
         </a>
         ]. Other trials are ongoing [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
         There is some evidence that mitochondrial dysfunction may play a role in the pathophysiology of PSP [
         <a href="#rid47">
          47
         </a>
         ]. In a preliminary six-week placebo-controlled trial of 21 patients with PSP, coenzyme Q10 improved brain energy metabolism via magnetic resonance spectroscopy and improved the PSP rating scale and the Frontal Assessment Battery [
         <a href="#rid48">
          48
         </a>
         ]. However, a subsequent one-year placebo-controlled trial of 61 subjects with PSP failed to demonstrate any disease-modifying effect of high-dose coenzyme Q10 [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3721230731">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disease progression in PSP usually occurs fairly rapidly and relentlessly [
         <a href="#rid50">
          50
         </a>
         ]. Most patients become dependent for care within three or four years from presentation. The disorder culminates in death at a median of six to nine years after the diagnosis [
         <a href="#rid51">
          51-56
         </a>
         ]. In addition, quality of life is significantly reduced [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         In a systematic review and meta-analysis, predictors of shorter survival included the PSP with Richardson syndrome (PSP-RS) phenotype compared with the PSP with parkinsonism (PSP-P) phenotype, early falls, and early cognitive symptoms (both more common in the PSP-RS phenotype) [
         <a href="#rid58">
          58-60
         </a>
         ]. Early onset of dysphagia, which is seen in both the PSP-RS and PSP-P phenotypes, was also predictive of shorter survival. The prognostic effect of the presence of a supranuclear gaze palsy was inconsistent across studies. Levodopa response, as often seen in the early stages of the PSP-P phenotype, did not predict longer survival. Emerging technology, including wearable sensors to provide objective, sensitive quantitative evaluation of gait changes in PSP, may be a complementary tool to predict disease severity and progression [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14136.html" rel="external">
          "Progressive supranuclear palsy (PSP): Clinical features and diagnosis", section on 'Variant phenotypes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1043408607">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease-modifying therapy
         </strong>
         – No disease-modifying therapies have yet been identified for progressive supranuclear palsy (PSP). A variety of therapies are under investigation, but results thus far have been disappointing. (See
         <a class="local">
          'Investigational therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic pharmacotherapy
         </strong>
         – Unlike in idiopathic Parkinson disease, levodopa and other dopaminergic therapies are not usually effective for motor parkinsonism in patients with PSP. Nonetheless, a trial of levodopa is reasonable in patients with predominant parkinsonism, as some patients can derive benefit, particularly at first. Ineffective therapies should not be continued long-term. (See
         <a class="local">
          'Pharmacologic treatments'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonpharmacologic interventions
         </strong>
         – Multidisciplinary interventions for PSP include speech and language therapy for managing dysphagia and dysarthria and occupational and physical therapy for managing activities of daily living, postural instability, and falls. Advance care planning should be addressed early in the disease course. (See
         <a class="local">
          'Multidisciplinary interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Caregiver support
         </strong>
         – Expert nursing support and patient advocacy groups are invaluable for providing helpful information to families and caregivers. (See
         <a class="local">
          'Support groups'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Disease progression in PSP usually occurs fairly rapidly and relentlessly compared with Parkinson disease. Most patients become dependent for care within three or four years from presentation. The disorder culminates in death at a median of six to nine years after the diagnosis. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McFarland NR. Diagnostic Approach to Atypical Parkinsonian Syndromes. Continuum (Minneap Minn) 2016; 22:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nozaki S, Fujiu-Kurachi M, Tanimura T, et al. Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study. Prog Rehabil Med 2021; 6:20210012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirakawa Y, Takeda K, Koyama S, et al. Effect of the Lee Silverman Voice Treatment BIG® on motor symptoms in a participant with progressive supranuclear palsy: A case report. Physiother Theory Pract 2023; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burn DJ, Warren NM. Toward future therapies in progressive supranuclear palsy. Mov Disord 2005; 20 Suppl 12:S92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krack P, Marion MH. "Apraxia of lid opening," a focal eyelid dystonia: clinical study of 32 patients. Mov Disord 1994; 9:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slade SC, Finkelstein DI, McGinley JL, Morris ME. Exercise and physical activity for people with Progressive Supranuclear Palsy: a systematic review. Clin Rehabil 2020; 34:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuda N, Takamatsu Y, Aiba I. Effect of therapeutic exercise on the balance of patients with progressive supranuclear palsy: A pilot study. Front Neurol 2022; 13:955893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croarkin E, Robinson K, Stanley CJ, Zampieri C. Training high level balance and stepping responses in atypical progressive supranuclear palsy: a case report. Physiother Theory Pract 2023; 39:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sosner J, Wall GC, Sznajder J. Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients. Arch Phys Med Rehabil 1993; 74:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clerici I, Ferrazzoli D, Maestri R, et al. Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments. PLoS One 2017; 12:e0170927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Villota VA, Terroba-Chambi C, Castillo-Torres SA, et al. Clinical correlates of fear of falling in progressive supranuclear palsy and multiple system atrophy. Eur J Neurol 2023; 30:2261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Curr Treat Options Neurol 2016; 18:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Respondek G, Breslow D, Amirghiasvand C, et al. The Lived Experiences of People with Progressive Supranuclear Palsy and Their Caregivers. Neurol Ther 2023; 12:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998; 55:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002; 17:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metta V, Chaudhuri KR, Leta V, et al. Real-life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1-year follow-up data report. Brain Behav 2022; 12:e2547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajput A, Rajput AH. Progressive supranuclear palsy: clinical features, pathophysiology and management. Drugs Aging 2001; 18:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan EK, Chan LL, Wong MC. Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Clin Neurol Neurosurg 2003; 105:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Defazio G, De Mari M, De Salvia R, et al. "Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report. Clin Neuropharmacol 1999; 22:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 2017; 16:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 1997; 3:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983; 13:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993; 16:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engel PA. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 1996; 44:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985; 35:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Hai S, Zhou Y, Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev 2015; 2015:CD009444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001; 57:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barclay CL, Duff J, Sandor P, Lang AE. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 1996; 46:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauser RA, Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov Disord 1994; 9:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 2005; 62:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2005; 20 Suppl 12:S83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brusa L, Iani C, Ceravolo R, et al. Implantation of the nucleus tegmenti pedunculopontini in a PSP-P patient: safe procedure, modest benefits. Mov Disord 2009; 24:2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scelzo E, Lozano AM, Hamani C, et al. Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. J Neurol Neurosurg Psychiatry 2017; 88:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samotus O, Parrent A, Jog M. Spinal cord stimulation therapy for gait dysfunction in progressive supranuclear palsy patients. J Neurol 2021; 268:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciocca M, Seemungal BM, Tai YF. Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease and Atypical Parkinsonism: A Systematic Review of Preclinical and Clinical Data. Neuromodulation 2023; 26:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boeve BF. Progressive supranuclear palsy. Parkinsonism Relat Disord 2012; 18 Suppl 1:S192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Temple S. Advancing cell therapy for neurodegenerative diseases. Cell Stem Cell 2023; 30:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domínguez JM, Fuertes A, Orozco L, et al. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem 2012; 287:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold M, Lorenzl S, Stewart AJ, et al. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 2012; 8:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014; 29:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014; 13:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poewe W, Mahlknecht P, Krismer F. Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. Mov Disord 2015; 30:1528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 2021; 20:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaswani PA, Olsen AL. Immunotherapy in progressive supranuclear palsy. Curr Opin Neurol 2020; 33:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong MJ. Progressive Supranuclear Palsy: an Update. Curr Neurol Neurosci Rep 2018; 18:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ries V, Oertel WH, Höglinger GU. Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy. J Mol Neurosci 2011; 45:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 2016; 3:e266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Testa D, Monza D, Ferrarini M, et al. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 2001; 22:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008; 131:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 2016; 86:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29:1758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           dell'Aquila C, Zoccolella S, Cardinali V, et al. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism Relat Disord 2013; 19:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winter Y, Spottke AE, Stamelou M, et al. Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis 2011; 8:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; 88:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bessemer R, Iansavichene A, Jenkins ME, et al. Clinical milestones as triggers for palliative care intervention in progressive Supranuclear palsy and multiple system atrophy. J Neurol Sci 2023; 448:120614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavone C, Weigand SW, Ali F, et al. Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy. Parkinsonism Relat Disord 2023; 107:105290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abate F, Russo M, Ricciardi C, et al. Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy. Parkinsonism Relat Disord 2023; 109:105345.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 113998 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27495201" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diagnostic Approach to Atypical Parkinsonian Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33644483" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37326324" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Effect of the Lee Silverman Voice Treatment BIG®on motor symptoms in a participant with progressive supranuclear palsy: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16092097" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Toward future therapies in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7845400" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : "Apraxia of lid opening," a focal eyelid dystonia: clinical study of 32 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31559853" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Exercise and physical activity for people with Progressive Supranuclear Palsy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36176548" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effect of therapeutic exercise on the balance of patients with progressive supranuclear palsy: A pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35098865" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Training high level balance and stepping responses in atypical progressive supranuclear palsy: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8489366" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28158197" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37183570" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical correlates of fear of falling in progressive supranuclear palsy and multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27526039" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36447110" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The Lived Experiences of People with Progressive Supranuclear Palsy and Their Caregivers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9708960" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pharmacological therapy in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12465065" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35943202" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Real-life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1-year follow-up data report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888346" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Progressive supranuclear palsy: clinical features, pathophysiology and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12691807" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10516881" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : "Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28653647" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18591078" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6847139" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Progressive supranuclear palsy: clinical features and response to treatment in 16 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8374914" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Retrospective study of drug response in 87 patients with progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10447452" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Zolpidem in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8790233" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3895032" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Treatment of progressive supranuclear palsy with tricyclic antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25734590" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502915" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8628467" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969219" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Initial experience with electroconvulsive therapy for progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15956104" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16092096" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Treatment of progressive supranuclear palsy and corticobasal degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19672983" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Implantation of the nucleus tegmenti pedunculopontini in a PSP-P patient: safe procedure, modest benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28214797" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33011852" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Spinal cord stimulation therapy for gait dysfunction in progressive supranuclear palsy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37452800" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease and Atypical Parkinsonism: A Systematic Review of Preclinical and Clinical Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22166432" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37084729" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Advancing cell therapy for neurodegenerative diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22102280" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Evidence for irreversible inhibition of glycogen synthase kinase-3βby tideglusib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22347799" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24532007" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24873720" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26227071" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33609476" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32657895" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Immunotherapy in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29455271" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Progressive Supranuclear Palsy: an Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21792607" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18464278" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27583276" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19233037" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11731878" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17405767" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A clinical rating scale for progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18385183" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27037234" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25370486" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23968651" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21576919" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Health-related quality of life in multiple system atrophy and progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28250027" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37001415" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical milestones as triggers for palliative care intervention in progressive Supranuclear palsy and multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36682219" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36868037" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
